U.S. FDA Grants Expanded Labeling Claim to On-X Life Technologies, Reducing Blood-Thinning Requirements for Heart Valve Patients Thousands With On-X Aortic Implant May Be Able to Reduce Medication Regimen AUSTIN, TX — April 2, 2015 — Thousands of Americans with On-X® Aortic Heart Valves may be able to reduce their regular blood-thinning medication regimen, thanks to […]
On-X LTI to present its newest advance in heart valve technology at AATS
April 24, 2014 By
On-X Life Technologies to present its newest advance in heart valve technology at “94th Annual Scientific Meeting” of the American Association for Thoracic Surgery (AATS) in Toronto AUSTIN, TX — April 24, 2014 — Privately held On-X® Life Technologies, Inc. (On-X LTI) announced today that it will present the results of the PROACT1 clinical trial […]
50-year retrospective study
April 4, 2014 By
50-year retrospective study shows On-X Life Technologies’ mechanical heart valves have “the lowest incidence of valve thrombosis” Data presented at 22nd Annual Meeting of the Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) AUSTIN, TX — April 4, 2014 — Privately held On-X® Life Technologies Inc., whose mechanical heart valves have been implanted in more […]
On-X LTI to present its newest advance in heart valve technology
April 2, 2014 By
On-X Life Technologies to present its newest advance in heart valve technology at the Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) in Istanbul, Turkey “We are excited about introducing the On-X® Plus 1.5™ Aortic Heart Valve to this important surgical society. This valve represents a new paradigm by which clinicians can manage their patients […]
On-X Life Technologies reports CE mark approval
January 14, 2014 By
On-X Life Technologies reports CE mark approval to sell its mechanical aortic heart valve with an expanded labeling claim: a reduction in the required use of blood thinners “This approval allows European clinicians to maintain patients on a lower dose of anticoagulant, which has been shown in a multicenter clinical trial (PROACT: Prospective On-X Anticoagulation […]
Interim Results From the PROACT Randomized FDA IDE Trial
November 13, 2013 By
Reduced Anticoagulation After Mechanical Aortic Valve Replacement Narrated slide presentation from The American Association for Thoracic Surgery Annual Meeting 2013, Minneapolis, Minnesota, USA, on May 6, 2013
